1. Home
  2. SKYE vs MBRX Comparison

SKYE vs MBRX Comparison

Compare SKYE & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$1.18

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

N/A

Current Price

$7.87

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SKYE
MBRX
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
6.4M
IPO Year
2013
2016

Fundamental Metrics

Financial Performance
Metric
SKYE
MBRX
Price
$1.18
$7.87
Analyst Decision
Buy
Strong Buy
Analyst Count
4
3
Target Price
$68.00
★ $240.00
AVG Volume (30 Days)
98.4K
★ 144.8K
Earning Date
11-24-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$0.16
52 Week High
$11.68
$11.47

Technical Indicators

Market Signals
Indicator
SKYE
MBRX
Relative Strength Index (RSI) 44.62 67.68
Support Level $0.26 $2.12
Resistance Level $1.66 $10.24
Average True Range (ATR) 0.20 0.91
MACD -0.00 -0.24
Stochastic Oscillator 62.05 24.43

Price Performance

Historical Comparison
SKYE
MBRX

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: